London – The European Medicines Agency will provide up-to-date guidance on Friday on how countries across Europe should use the AstraZeneca-developed coronavirus vaccine.
Earlier this month, Amsterdam-based drug regulators in the European Union of 27 countries said there was a “potential link” between the AstraZeneca vaccine and rare blood coagulation disorders, but would receive an injection. The benefits outweighed the risks.
Authorities experts have since offered a second shot to those who received the first dose of AstraZeneca, and are there specific risk factors that may predispose some to developing abnormal blood clots? We are considering related issues such as whether or not.
The EMA previously described blood clots as a “very rare” side effect and stated that the vaccine label needs to be changed to be noticed by doctors and patients.
It is still unknown how often rare blood clots occur. As of late March, 30 of the 18 million doses were such cases, according to data from the United Kingdom, which receives more AZ vaccine than any other country.
Last month, we stopped using the AstraZeneca vaccine in more than 12 countries, mainly in Europe, because of blood clot problems. Most have resumed — some have age restrictions — after the EMA has stated that countries should continue to use the vaccine.
This week, authorities identified a similar possible link between blood clots and the COVID-19 vaccine developed by Johnson & Johnson. As with AstraZeneca products, the EMA recommended changing the label, but said the benefits of vaccination outweigh the risks.
Copyright 2021 AP communication. all rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
EU agency issuing guidance on AstraZeneca’s COVID shots
Source link EU agency issuing guidance on AstraZeneca’s COVID shots